Our EOU unit certified by ISO 14001:2004

Our R&D Centre is approved by DSIR, Govt of India on 19.01.2011

Our facility is audited and approved by PMDA-Japan on 25.01.2011

COS received from EDQM for Gemcitabine HCl EP (R0-CEP 2006-222-Rev 00 )

Korean FDA Approved for Gemcitabine HCl & Ambroxol HCl COS received from EDQM for Carboplatin (R0-CEP 2006-212-Rev.00)

COS received from EDQM for Buflomedil HCl (R0-CEP 2006-080-Rev.00)

COS received from EDQM for Oxaliplatin EP (R0-CEP 2006-201-Rev.00)

Ambroxol MF Holder & Site Registered with PMDA, Japan

Site inspected Effectively by TGA, Australia

Export Excellence Award-2010 received from FKCCI & VITC, Bangalore

Obtained EUGMP Certificate for Gemcitabine HCl EP from AFSSAPS, France

Obtained EUGMP Certificate for Temozolomide (Unit-1) & Capecitabine (Unit-2) from BSG, Hamburg

Obtained EUGMP Certificate for Anastrozole, Irinotecan & Oxaliplatin from INFARMED, Portugal

Filed USDMF of Anastrozole, Temozolomide, Irinotecan, Oxaliplatin with USFDA

Patent Filed for Novel Polymorphic Form of Bortezomib (160/CHE/2010)